company background image
B8F logo

Biofrontera XTRA:B8F Stock Report

Last Price

€0.35

Market Cap

€22.1m

7D

2.4%

1Y

-70.5%

Updated

28 Mar, 2024

Data

Company Financials

B8F Stock Overview

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products.

B8F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Biofrontera AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biofrontera
Historical stock prices
Current Share Price€0.35
52 Week High€1.30
52 Week Low€0.30
Beta0.69
1 Month Change1.17%
3 Month Change-13.47%
1 Year Change-70.47%
3 Year Change-85.95%
5 Year Change-94.48%
Change since IPO-97.74%

Recent News & Updates

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

Mar 07
Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19
We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Recent updates

Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

Mar 07
Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge

We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Feb 19
We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate

Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Dec 07
Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year

Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Jun 08
Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?

Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 14
Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Shareholder Returns

B8FDE PharmaceuticalsDE Market
7D2.4%4.0%2.5%
1Y-70.5%-24.6%7.0%

Return vs Industry: B8F underperformed the German Pharmaceuticals industry which returned -25.9% over the past year.

Return vs Market: B8F underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is B8F's price volatile compared to industry and market?
B8F volatility
B8F Average Weekly Movement13.6%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: B8F's share price has been volatile over the past 3 months.

Volatility Over Time: B8F's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199792n/ahttps://www.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin.

Biofrontera AG Fundamentals Summary

How do Biofrontera's earnings and revenue compare to its market cap?
B8F fundamental statistics
Market cap€22.14m
Earnings (TTM)-€8.60m
Revenue (TTM)€28.63m

0.8x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B8F income statement (TTM)
Revenue€28.63m
Cost of Revenue€5.71m
Gross Profit€22.92m
Other Expenses€31.53m
Earnings-€8.60m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin80.07%
Net Profit Margin-30.06%
Debt/Equity Ratio0.3%

How did B8F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.